ORIGINAL PAPERS

   BREAST CANCER

Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy

Valentina Guarneri, PierFranco Conte
The Oncologist 2009; 14: 645-656; doi:10.1634/theoncologist.2009-0078
[Abstract] [Full Text] [PDF]  

SUMMARY: This review contextualizes the data from clinical trials of metastatic breast cancer into different clinical scenarios of metastatic disease, taking into account the molecular subtype and prior adjuvant treatments. Increasingly, the more efficacious agents have been progressively incorporated into adjuvant treatment, making the optimal therapeutic strategy for patients with metastatic disease largely based on prior exposure to adjuvant therapies.

Studying Genetic Variations in Cancer Prognosis (and Risk): A Primer for Clinicians

Sevtap Savas, Geoffrey Liu
The Oncologist 2009; 14: 657-666; doi:10.1634/theoncologist.2009-0042
[Abstract] [Full Text] [PDF]  

SUMMARY: This review summarizes the current knowledge on how candidate genes and genetic variations are selected to evaluate gene–outcome, gene–prognosis, and gene–treatment response relationships as applicable to the practicing oncologist.

The Role of Src in Solid Tumors

Deric L. Wheeler, Mari Iida, Emily F. Dunn
The Oncologist 2009; 14: 667-678; doi:10.1634/theoncologist.2009-0009
[Abstract] [Full Text] [PDF]  

SUMMARY: This review discusses the role of Src family kinases in solid tumors and the recent therapeutic advances aimed at targeting this family of tyrosine kinases in cancer.

Methylnaltrexone

Jeroen J.M.A. Hendrikx, Jos H. Beijnen, Jan H.M. Schellens
The Oncologist 2009; 14: 679-682; doi:10.1634/theoncologist.2009-0049
[Full Text] [PDF]  

SUMMARY: This article provides a brief summary of the use of methylnaltrexone for opioid-induced constipation in patients with advanced illness receiving palliative care when the response to laxatives is insufficient.

The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

C. William Helm
The Oncologist 2009; 14: 683-694; doi:10.1634/theoncologist.2008-0275
[Abstract] [Full Text] [PDF]  

SUMMARY: This article reviews the current literature and discusses the possible role for hyperthermic i.p. chemotherapy in epithelial ovarian cancer at significant natural history time points: front line, at the time of interval debulking, in consolidation, and for recurrent disease. Further research is needed, but this technique could sensibly be researched at all the natural history time points of this disease.

Sentinel Lymph Node Biopsy in the Management of Vulvar Carcinoma, Cervical Cancer, and Endometrial Cancer

Oliver Zivanovic, Fady Khoury-Collado, Nadeem R. Abu-Rustum, Mary L. Gemignani
The Oncologist 2009; 14: 695-705; doi:10.1634/theoncologist.2009-0075
[Abstract] [Full Text] [PDF]  

SUMMARY: This review examines the body of literature related to gynecologic cancer malignancies and sentinel lymph node biopsy.

The Future of Targeted Therapies in Ovarian Cancer

Susana Banerjee, Martin Gore
The Oncologist 2009; 14: 706-716; doi:10.1634/theoncologist.2009-0013
[Abstract] [Full Text] [PDF]  

SUMMARY: This article reviews the various targeted therapeutic approaches under clinical investigation in ovarian cancer and the challenges facing their future success in the clinic.

Serum -Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma

Sadhna R. Vora, Hui Zheng, Zsofia K. Stadler, Charles S. Fuchs, Andrew X. Zhu
The Oncologist 2009; 14: 717-725; doi:10.1634/theoncologist.2009-0038
[Abstract] [Full Text] [PDF]  

SUMMARY: This study evaluated the role of serum -fetoprotein as a marker for treatment response in patients with hepatocellular carcinoma receiving systemic therapy using a retrospective analysis of patients enrolled in five phase II clinical trials. The study found that serum -fetoprotein change during treatment may serve as a useful surrogate marker for clinical outcome in these patients.

Role of Hematopoietic Stem Cell Transplant in the Management of Follicular Lymphoma

Matthew Foster, Don A. Gabriel, Thomas Shea
The Oncologist 2009; 14: 726-738; doi:10.1634/theoncologist.2009-0045
[Abstract] [Full Text] [PDF]  

SUMMARY: This review aims to clarify recently published data on the application of hematopoietic stem cell transplant in advanced follicular lymphoma.

Nodular Lymphocyte Predominant Hodgkin Lymphoma

Alfred Ian Lee, Ann S. LaCasce
The Oncologist 2009; 14: 739-751; doi:10.1634/theoncologist.2009-0099
[Abstract] [Full Text] [PDF]  

SUMMARY: This study reviews the clinical features, histopathologic features, and differential diagnosis of nodular lymphocyte predominant Hodgkin lymphoma, and summarizes the current treatment options available for and outcomes of patients with this disease.

Factors That Affect the Duration of the Interval Between the Completion of Palliative Chemotherapy and Death

Kenji Hashimoto, Kan Yonemori, Noriyuki Katsumata, Marika Hotchi, Tsutomu Kouno, Chikako Shimizu, Kenji Tamura, Masashi Ando, Masahiro Takeuchi, Yasuhiro Fujiwara
The Oncologist 2009; 14: 752-759; doi:10.1634/theoncologist.2008-0257
[Abstract] [Full Text] [PDF]  

SUMMARY: This study investigated the duration of the interval between the completion of palliative chemotherapy and death in clinical practice and identified factors that shorten it.

Reflections

Petra J. Loesch
The Oncologist 2009; 14: 3028-3031; doi:10.1634/theoncologist.2009-7001
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.